In recent years, exchange-traded funds tracking the healthcare sector, the third-largest sector weight in the S&P 500, have become increasingly refined.
For example, since late 2014, ETFs have come to market that offer investors exposure to biotech stocks at specific stages of FDA clinical trials. Last year, an ETF debuted dedicated to stocks with heavy emphasis on cancer drugs and treatments.
The New Name
So, the Market Vectors Generic Drugs ETF (NASDAQ: GNRX), which launched Wednesday, is by no means an outlandish concept. Given the boom in the generic drugs industry over the past several years and the group's status as a prime destination for large-scale mergers and acquisitions activity, the Market Vectors Generic Drugs ETF is actually an idea that makes a lot of sense.
“Expiring patents on various brand name drugs and ...
/www.benzinga.com/general/biotech/16/01/6141538/new-etf-is-a-refined-pharmaceuticals-play alt=New ETF Is A Refined Pharmaceuticals Play>Full story available on Benzinga.com
More...